MIRA Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic
MIRA Pharmaceuticals, Inc. (MIRA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$32.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-03-31
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$5.98M.
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$22.69M.
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$2.40M.
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$2.04M.
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$32.00M.
- MIRA Pharmaceuticals, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$7.85M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$28.68M derived: sum of 2 quarters · filed 2026-03-31 | -$32.00M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$22.69M 10-Q · filed 2025-11-13 | -$26.02M 10-Q · filed 2025-11-13 | ||
| 2024-12-31 | -$2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.44M derived: sum of 2 quarters · filed 2026-03-31 | -$7.85M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$2.04M 10-Q · filed 2025-11-13 | -$5.45M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |